VIR - Vir Biotechnology, Inc. News

Vir Biotechnology Receives FDA Fast Track Designation For VIR-5500 To Treat Metastatic Castration-Re

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FD

Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S.

uniQure (NASDAQ:QURE) and Vir Biotechnology (NASDAQ:VIR) Critical Review

Vir Biotechnology (NASDAQ: VIR - Get Free Report) and uniQure (NASDAQ: QURE - Get Free Report) are b

HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $22

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Vir Biotechnology (NASDAQ:VIR) with

gurufocus.com

Vir Biotechnology Appoints David Liu as Chief Medical Officer

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of David Liu, M.D., Ph.D., as

Vir Biotechnology Appoints David Liu as Chief Medical Officer

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointmen

Vir Biotechnology To Reveal Expanded Phase 2 SOLSTICE Results for Elebsiran And Tobevibart In Hepati

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will present data from the Phase 2

Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepat

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company wi

Vir Biotechnology Appoints Aziz Sawaf CFO, Effective Oct. 5

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Aziz Sawaf, MBEE, MBA, CFA,

Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer.

seekingalpha.com

Vir Biotechnology: Astellas Deal Highlights The Platform's Value

Vir Biotechnology is now a two-engine company, with major pharma partnerships and a fully enrolled h

Engineers Gate Manager LP Sells 121,964 Shares of Vir Biotechnology, Inc. $VIR

Engineers Gate Manager LP trimmed its stake in Vir Biotechnology, Inc. (NASDAQ: VIR) by 48.7% during

Head-To-Head Comparison: Crescent Biopharma (NASDAQ:CBIO) vs. Vir Biotechnology (NASDAQ:VIR)

Vir Biotechnology (NASDAQ: VIR - Get Free Report) and Crescent Biopharma (NASDAQ: CBIO - Get Free Re

Bank of New York Mellon Corp Makes New $7.08 Million Investment in Vir Biotechnology, Inc. $VIR

Bank of New York Mellon Corp bought a new stake in Vir Biotechnology, Inc. (NASDAQ: VIR) during the

Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne

Algert Global LLC Purchases 315,969 Shares of Vir Biotechnology, Inc. $VIR

Algert Global LLC grew its holdings in shares of Vir Biotechnology, Inc. (NASDAQ: VIR) by 64.6% duri

ADAR1 Capital Management LLC Acquires New Shares in Vir Biotechnology, Inc. $VIR

ADAR1 Capital Management LLC bought a new stake in Vir Biotechnology, Inc. (NASDAQ: VIR) during the

seekingalpha.com

Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript

Vir Biotechnology Q2 Earnings Call Highlights

Vir Biotechnology (NASDAQ: VIR) reported second-quarter 2026 results alongside updates on its chroni

marketbeat.com

Vir Biotechnology Q2 Earnings Call Highlights

Vir Biotechnology NASDAQ: VIR reported second-quarter 2026 results alongside updates on its chronic

zacks.com

Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates

Vir Biotechnology, Inc. (VIR) came out with quarterly earnings of $0.47 per share, missing the Zacks

Vir Biotechnology Q2 EPS $0.47 Beats $0.18 Estimate, Sales $238.946M Beat $216.456M Estimate

Vir Biotechnology (NASDAQ:VIR) reported quarterly earnings of $0.47 per share which beat the analyst

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate up

gurufocus.com

Vir Biotechnology Announces Chief Financial Officer Transition

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sabatini, Senior Vice President and

Vir Biotechnology Announces Chief Financial Officer Transition

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sab

Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $27

Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight

Leerink Partners Maintains Outperform on Vir Biotechnology, Raises Price Target to $21

Leerink Partners analyst Roanna Ruiz maintains Vir Biotechnology (NASDAQ:VIR) with a Outperform a

Vir Biotechnology To Present Data From Its Phase 2 SOLSTICE Study Of Obevibart And Elebsiran Combina

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will present data from the Phase 2

Earnings Scheduled For May 6, 2026

Vir Biotechnology Q1 2026 GAAP EPS $(0.85) Up From $(0.88) YoY, Sales $(29.000K) Down From $3.032M Y

Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(0.85) per share. This is a 3.41 percen

Vir Biotech Doses First Patient In Phase 1 Expansion Trial Of VIR-5500 For Metastatic Prostate Cance

Phase 1 trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 i

Semtech To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday

Wall Street analysts changed outlook on top names. For full view of changes, including upgrades/down

HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $20

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Vir Biotechnology (NASDAQ:VIR) with

C3.ai Posts Downbeat Results, Joins Trade Desk, FTAI Aviation And Other Big Stocks Moving Lower In T

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Why Marriott Vacations Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket

Barclays Maintains Overweight on Vir Biotechnology, Raises Price Target to $30

Barclays analyst Etzer Darout maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and rais

Vir Biotechnology Commences $200M Common Stock Offering

Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powerin

These Analysts Boost Their Forecasts On Vir Biotechnology

Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $24

Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight

Nasdaq Gains Over 1%; Keurig Dr Pepper Earnings Top Views

12 Health Care Stocks Moving In Tuesday's Intraday Session

Henry Schein, Vir Biotechnology, Ultra Clean Holdings And Other Big Stocks Moving Higher On Tuesday

Stock Market Today: S&P 500 Futures Slip As Dow, Nasdaq 100 Gain Following Trump's Tariff Threat — W

(Editor’s note: The future prices of benchmark tracking ETFs, the lede, the economic data, and the h

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Why Keysight Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket

Earnings Scheduled For February 23, 2026

Earnings Scheduled For November 5, 2025

This Astera Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday